Azurity Archives
News and events as they happen
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
MEDIA ALERT: WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome positive…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
NYMALIZE® (NIMODIPINE) ORAL SOLUTION 30 MG/5 ML PREFILLED ENFIT® SYRINGE
MEDIA ALERT: WOBURN, Mass. September 3, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Nymalize® (nimodipine) oral solution in a 30 mg/5 mL prefilled ENFit® syringe…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
MYHIBBIN™ (mycophenolate mofetil oral suspension)
MEDIA ALERT: WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™…
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
MEDIA ALERT: – January 24, 2024 – Woburn, Massachusetts, Azurity Pharmaceuticals, Inc. is voluntarily recalling one (1) lot (F230169A) of
Zenzedi® CII (dextroamphetamine sulfate tablets, USP) 30 mg to the consumer level. The product is being recalled due to a report…
